Faron Pharmaceuticals Oy Grant of options (6156P)

TIDMFARN

RNS Number : 6156P

Faron Pharmaceuticals Oy

21 November 2016

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Grant of options

TURKU - FINLAND, 21 November 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, announces that on 18 November 2016 the Board of Faron granted 400,000 options over ordinary shares in the Company ("Options") under the Faron 2015 Option Plan at an exercise price of 290 euro cents per share. The options are exercisable between 8 October 2016 and 30 September 2021. The details of the 2015 Option Plan are described in the AIM Admission Document dated 11 November 2015, which is available on Company's website.

The granted 400,000 options represent 1.49% of the fully-diluted Ordinary Share Capital of the Company.

Included in the number of options granted on 18 November 2016, the following options were issued to Directors and other Persons Discharging Managerial Responsibility ("PDMRs"):

 
 Director                  Options granted 
 
 Frank Armstrong                    40,000 
 Matti Manner                       20,000 
 Markku Jalkanen                    80,000 
 Yrjö E K Wichmann             30,000 
 Juho Jalkanen                      20,000 
 Jonathan Knowles                   20,000 
 Huaizheng Peng                     20,000 
 Leopoldo Zambeletti                20,000 
 Total directors                   250,000 
 
 
 PDMRs 
 Ilse Piippo        37 400 
 Mikael Maksimow    28 100 
 Matti Karvonen     28 100 
 Total PDMRs        93 600 
 

For more information please contact:

Faron Pharmaceuticals Ltd

Katja Wallenlind

Phone [phone]

E-mail: [e-mail]

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: [phone]

E-mail: [e-mail]

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson, Rebecca Anderson

Phone: [phone]

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: [phone]

Whitman Howard Limited, Nominated Broker

Ranald McGregor-Smith, Francis North

Phone: [phone]

About Faron Pharmaceuticals Ltd

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, cancer immunotherapy and vascular damage. The pipeline is built on Faron's scientific knowledge and control of the endothelial barrier, the membrane of cells lining blood and lymphatic vessels to separate blood content from tissues. The Company's lead candidate Traumakine(R) is in development for the treatment of Acute Respiratory Distress Syndrome ("ARDS"), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine is currently in pan-European (INTEREST) and Japanese pivotal Phase III studies. Additionally, Faron is developing Clevegen(R) a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to convert the immune environment around a tumour from being immune suppressive to immune stimulating. This novel macrophage-directed immuno-oncology approach is called Tumour Immunity Enabling Technology ("TIET") and can be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. New application opportunities related to TIET cover chronic infections and inefficient vaccination. Based in Turku, Finland, Faron Pharmaceuticals is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
-------------------------------------------------------------------------------------------- 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
----  -------------------------------------------------------------------------------------- 
 a.    Name(s)                          1. Dr Markku Jalkanen 
                                         2. Dr Frank Armstrong 
                                         3. Matti Manner 
                                         4. Dr Juho Jalkanen 
                                         5. Yrjö Wichmann 
                                         6. Leopoldo Zambeletti 
                                         7. Dr Huaizheng Peng 
                                         8. Professor Jonathan Knowles 
                                  ---------------------------------------------------------- 
 2     Reason for notification 
----  --------------------------  ---------------------------------------------------------- 
 a.    Position/Status             Directors of the Company 
----  --------------------------  ---------------------------------------------------------- 
 b.    Initial notification/       Initial Notification 
        Amendment 
----  --------------------------  ---------------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------------------- 
 a.    Name                        Faron Pharmaceuticals Oy 
----  --------------------------  ---------------------------------------------------------- 
 b.    LEI                         7437009H31TO1DC0EB42 
----  --------------------------  ---------------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
----  -------------------------------------------------------------------------------------- 
 a.    Description of              Options over ordinary shares 
        the financial 
        instrument, type            ISIN: FI4000153309 
        of instrument 
 
        Identification 
        Code 
----  --------------------------  ---------------------------------------------------------- 
 b.    Nature of the               Grant of Options to subscribe for Ordinary 
        transaction                 Shares 
----  --------------------------  ---------------------------------------------------------- 
 
 c.    Price(s) and volume(s)          Price(s)            Volume(s) 
----  --------------------------      ------------------  ----------- 
                                             1. EUR2.90     80,000 
                                              2. EUR2.90     40,000 
                                              3. EUR2.90     20,000 
                                              4. EUR2.90     20,000 
                                              5. EUR2.90     30,000 
                                              6. EUR2.90     20,000 
                                              7. EUR2.90     20,000 
                                              8. EUR2.90     20,000 
                                      ------------------  ----------- 
 
       Aggregated information 
 
        - Aggregated Volume 
 
 d.     - Price                    250,000 
----  --------------------------  ---------------------------------------------------------- 
 e.    Date of the transaction     18 November 2016 
----  --------------------------  ---------------------------------------------------------- 
 f.    Place of the transaction    Turku 
----  --------------------------  ---------------------------------------------------------- 
 
 
 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
-------------------------------------------------------------------------------------------- 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
----  -------------------------------------------------------------------------------------- 
 a.    Name                             1. Ilse Piippo 
                                         2. Mikael Mksimow 
                                         3. Matti Karvonen 
                                  ---------------------------------------------------------- 
 2     Reason for notification 
----  --------------------------  ---------------------------------------------------------- 
 a.    Position/Status             Person discharging managerial responsibilities 
----  --------------------------  ---------------------------------------------------------- 
 b.    Initial notification/       Initial Notification 
        Amendment 
----  --------------------------  ---------------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------------------- 
 a.    Name                        Faron Pharmaceuticals Oy 
----  --------------------------  ---------------------------------------------------------- 
 b.    LEI                         7437009H31TO1DC0EB42 
----  --------------------------  ---------------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
----  -------------------------------------------------------------------------------------- 
 a.    Description of              Options over ordinary shares 
        the financial 
        instrument, type            ISIN: FI4000153309 
        of instrument 
 
        Identification 
        Code 
----  --------------------------  ---------------------------------------------------------- 

 b.    Nature of the               Grant of Options to subscribe for Ordinary 
        transaction                 Shares 
----  --------------------------  ---------------------------------------------------------- 
 
 c.    Price(s) and volume(s)          Price(s)            Volume(s) 
----  --------------------------      ------------------  ----------- 
                                             1. EUR2.90     37,400 
                                              2. EUR2.90     28,100 
                                              3. EUR2.90     28,100 
                                      ------------------  ----------- 
 
       Aggregated information 
 
        - Aggregated Volume 
 
 d.     - Price                    93,600 
----  --------------------------  ---------------------------------------------------------- 
 e.    Date of the transaction     18 November 2016 
----  --------------------------  ---------------------------------------------------------- 
 f.    Place of the transaction    Turku 
----  --------------------------  ---------------------------------------------------------- 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHAKFDQPBDDKDD

(END) Dow Jones Newswires

November 21, 2016 02:00 ET (07:00 GMT)